Can brain network connectivity facilitate the clinical development of disease-modifying anti-Alzheimer drugs?

Brain Communications, Journal Year: 2024, Volume and Issue: 7(1)

Published: Dec. 18, 2024

Abstract The preclinical phase of Alzheimer’s disease represents a crucial time window for therapeutic intervention but requires the identification clinically relevant biomarkers that are sensitive to effects disease-modifying drugs. Amyloid peptide and tau proteins, main histological hallmarks disease, have been widely used as anti-amyloid anti-tau However, these do not fully capture multiple biological pathways brain. Indeed, robust amyloid-target engagement by monoclonal antibodies has recently translated into modest cognitive clinical benefits in patients, albeit with potentially life-threatening side effects. Moreover, targeting pathway yet result any positive outcomes. Findings from computational neuroscience demonstrated brain regions work isolation interconnected within complex network structures. Brain connectivity studies suggest misfolded proteins can spread through connections, leading hypothesis is pathology disconnectivity. Based on assumptions, here we discuss how incorporating outcomes could better global functionality and, conjunction traditional biomarkers, facilitate development new anti-Alzheimer’s

Language: Английский

Targeted Magnetic Nanoparticles for Beta-Amyloid Detection

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(11), P. 1395 - 1395

Published: Oct. 29, 2024

The presence of beta-amyloid plaques is a part the pathogenesis Alzheimer's disease, but there currently no universally accepted method for magnetic resonance (MR) imaging disease. However, it known that nanoparticles (MNPs) can improve T2 contrast in MR images various targets.

Language: Английский